Skip to main content

Table 2 Associations of overweight/obese BMI with ER-positive and ER-negative breast cancer, by menopausal status for 1823 cases and 4720 controls

From: Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype

 

Normal/underweight

BMI < 25 kg/m2

Overweight/obese

BMI ≥ 25 kg/m2

Cases

Controls

OR (95% CI)

Cases

Controls

BMI association (unadjusted for density)

OR (95% CI)a

P het c

BMI association (adjusted for density)

OR (95% CI)b

P het c

Premenopausal

      

0.07

 

0.04

 ER-positive cancer

325

979

1.00 (ref)

180

528

1.06 (0.86–1.32)

 

1.53 (1.21–1.94)

 

 ER-negative cancer

58

979

1.00 (ref)

47

528

1.58 (1.05–2.38)

 

2.51 (1.61–3.93)

 

Postmenopausal HT user

      

0.95

 

0.75

 ER-positive cancer

240

678

1.00 (ref)

171

446

1.16 (0.92–1.47)

 

1.58 (1.23–2.04)

 

 ER-negative cancer

41

678

1.00 (ref)

27

446

1.14 (0.69–1.90)

 

1.44 (0.84–2.48)

 

Postmenopausal HT non-user

      

0.24

 

0.13

 ER-positive cancer

228

1029

1.00 (ref)

394

1060

1.69 (1.40–2.04)

 

2.28 (1.86–2.81)

 

 ER-negative cancer

51

1029

1.00 (ref)

61

1060

1.32 (0.89–1.94)

 

1.62 (1.06–2.47)

 
  1. Abbreviations: BMI body mass index, CI confidence interval, ER estrogen receptor, HT hormone therapy, OR odds ratio
  2. aOdds ratios estimated from polytomous multivariable logistic regression models adjusted for age, study
  3. bOdds ratios estimated from polytomous multivariable logistic regression models adjusted for age, study, and percent density
  4. cP value of heterogeneity of BMI by subtype association